Protagonist Therapeutics (PTGX) Stock Price, News & Analysis

Company Overview

Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on developing peptide-based medicines for immune-mediated diseases and hematologic disorders. The company uses its peptide discovery and development platform to create therapies designed to selectively modulate disease-related biological pathways.

Protagonist’s pipeline has included icotrokinra (also known as JNJ-2113), an oral peptide that targets the interleukin-23 receptor and is being developed for inflammatory and immune-mediated conditions in collaboration with Johnson & Johnson. The company has also developed rusfertide, a hepcidin mimetic intended to regulate iron metabolism and address conditions involving excessive red blood cell production; rights to rusfertide have been partnered with Takeda Pharmaceutical.

Founded in 2006 and headquartered in Newark, New Jersey, Protagonist Therapeutics serves global pharmaceutical and biotechnology markets through its internal research programs and collaborations with larger healthcare companies. The company is led by Dinesh V. Patel, Ph.D., who serves as president and chief executive officer. Its common stock trades on the Nasdaq under the symbol PTGX.

Key Stats

• Today's Range: $144.50 to $147.71
• 50-Day Range: $132.02 to $158.62
• 52-Week Range: $62.24 to $160.81
• Volume: 802,036 shs
• Average Volume: 581,223 shs
• Market Capitalization: $9.39 billion
• P/E Ratio: 140.85
• Dividend Yield: N/A
• Price Target: $147.13
• Consensus Rating: Moderate Buy

Protagonist Therapeutics Stock Analysis - MarketRank™

Protagonist Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 686th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Protagonist Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on no strong buy ratings, 16 buy ratings, 2 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Protagonist Therapeutics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Protagonist Therapeutics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Protagonist Therapeutics are expected to decrease in the coming year, from $4.22 to ($0.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Protagonist Therapeutics is 140.85, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.14.

Price to Earnings Ratio vs. Sector

The P/E ratio of Protagonist Therapeutics is 140.85, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.14.

Price to Book Value per Share Ratio

Protagonist Therapeutics has a P/B Ratio of 14.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.57% of the float of Protagonist Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Protagonist Therapeutics has a short interest ratio ("days to cover") of 15.34, which indicates bearish sentiment.

Change versus previous month

Short interest in Protagonist Therapeutics has recently decreased by 1.02%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Protagonist Therapeutics does not currently pay a dividend.

Dividend Growth

Protagonist Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Protagonist Therapeutics has a news sentiment score of 1.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Protagonist Therapeutics this week, compared to 5 articles on an average week.

Search Interest

Only 2 people have searched for PTGX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added Protagonist Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,192,827.00 in company stock.

Percentage Held by Insiders

5.19% of the stock of Protagonist Therapeutics is held by insiders.

Percentage Held by Institutions

98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/22/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PTGX
• CIK: 1377121
• Web: www.protagonist-inc.com
• Phone: (510) 474-0170
• Fax: N/A
• Employees: 141
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Protagonist Therapeutics: $147.13
• High Price Target: $190.00
• Low Price Target: $82.00
• Potential Upside/Downside: +1.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.03
• Trailing P/E Ratio: 140.85
• Forward P/E Ratio: 34.38
• P/E Growth: N/A
• Net Income: -$130.15 million
• Net Margins: 29.40%
• Pretax Margin: 29.91%
• Return on Equity: 12.03%
• Return on Assets: 11.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 21.71
• Quick Ratio: 21.71

Sales & Book Value

• Annual Sales: $46.02 million
• Price / Sales: 203.99
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.83 per share
• Price / Book: 14.76

Miscellaneous

• Outstanding Shares: 64,710,000
• Free Float: 61,350,000
• Market Cap: $9.39 billion
• Optionable: Optionable
• Beta: 1.80